Source comparison
Tesamorelin + Ipamorelin Blend: Dosing Comparison
The table below compares monotherapy dosing parameters with the observed dual-peptide protocol for tesamorelin + ipamorelin blend synergistic GH therapy. Dosing is lower in combination protocols due to synergistic GH amplification. Tesamorelin Dose 2mg once da
This comparison does not assign a generated winner or score.
- The table below compares monotherapy dosing parameters with the observed dual-peptide protocol for tesamorelin + ipamorelin blend synergistic GH therapy. Dosing is lower in combination protocols due to synergistic GH amplification.
- Tesamorelin Dose
- 2mg once daily
- N/A
- 1–2mg once daily (pre-bed)
- Reduced dose maintains efficacy due to ipamorelin synergy
- Ipamorelin Dose
- 200–300 mcg 3× daily
- 200–300 mcg 2–3× daily
- Frequency maintained but per-dose amount may reduce slightly
- Peak GH Elevation
- 3–5× baseline
- 4–6× baseline
- 7–10× baseline
- Multiplicative effect exceeds sum of individual peptides
- IGF-1 Increase (ng/mL)
- +80–100 from baseline
- +60–80 from baseline
- +120–160 from baseline
- Sustained elevation across 24-hour cycle, not just post-injection
- Cycle Duration
- 12–16 weeks
- 8–12 weeks
- 12 weeks on, 4 weeks off
- Cycling prevents pituitary desensitization and maintains peak response
- Visceral Fat Reduction (%)
- 15–18% at 26 weeks
- Minimal (2–4%)
- 18–22% at 26 weeks
- Tesamorelin drives VAT loss; ipamorelin preserves lean mass during deficit
- Side Effect Profile
- Nausea (12%), injection site reactions, transient hyperglycemia
- Minimal. No cortisol/prolactin elevation
- Similar to tesamorelin alone, but lower incidence due to reduced dosing
- Dual-peptide allows dose reduction without sacrificing GH response